BPD Biologics Process Development Conference Banner
← Back to News
Industry News2026/10/22

2026BPD Chengdu Conference Final Schedule! Upgrade to a full pass for just 0 yuan | See you 11-6

2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted by Eumedic, co-organized by Kelun-Biotech, with Jingze Bio, Haibowei Pharma, Zhishan Weixin, and Wiszhen Bio serving as Innovation Partners.

Gather on-site2000+Professional Buyers,70+Keynote Speakers, Built for ImpactTechnical Forum, Full-Chain Exhibition, BPD Match, Executive RoundtableThe multi-faceted sessions, centered on technical reports and case studies, facilitate CMC professional exchanges by building an efficient platform focused on deep expertise and practical problem-solving.Get a quick look at the latest conference schedule. Register now for a free meal voucher, or contact Xiao Yi to upgrade your pass for 0 yuan!


Conference Schedule Updated

Schedule updated through 10/16

11 5, Venue 1

Opening Forum: Industrial Ecosystem & Full Process Chain

09:00-09:05 Opening Remarks

09:05-09:50 Interview: Source Innovation and Global Competition: New Paradigms and Cycles for Chinese Innovative Drug Companies

Moderator: Li Kechun, Partner at Yuan Sheng Capital

Guest: Xiang Yu, CEO of Boryao Biologics

Zheng Yubo, CFO of Chengdu Tianfu International Bio-city Development Group and General Manager of Guosheng Capital

Chen Dexiang, Chairman & General Manager, Makang Bio

09:50-10:30 Interview: Differentiated Strategies of Frontier Molecules

Guest: Chen Su, General Manager of Chengdu Weijin Biology

Li Weimin, Abio Bio, President of Preclinical R&D

Li Jianguang, Haichang Bio, CSO

Li Shude, former Chief Manufacturing Officer at China Resources BiologyNEW

Innovative Development of Upstream Biopharmaceutical Processes

11:00-11:20 Report: Design of Multifunctional Fusion Proteins and CMC Development Strategies

Guest: Wang Zhenyu, Senior Director, GEMCare

11:20-11:40 Report: Cutting-Edge Strategies for Developing High-Yield Cell Lines for Complex Molecules

Guest: Zhang Yu, Vice Director of Process Development, Sanjiu Guojian

11:40-12:00 Report: Process Feasibility for Ongoing Projects

Speaker: Zhao Yanyan, Senior Director of Process Development Center, Bo-Ant Biopharma

12:00-12:20 Report: ADC Process Development Direction

Guest: Dong Fusheng, Operations Director, Chongqing Haoyuan

12:20-12:30 Q&A

12:30-13:30 Lunch Chat

Innovation Development of Downstream Biopharmaceutical Processes

13:30-13:50 Report: Design and Process Development of Fusion Proteins

Guest: Huang Haiqiu, Vice Dean and Director of R&D, Jeku Biotech

13:50-14:10 Report: Enhancing Downstream Processing Technologies: Application of Membrane Chromatography in Antibody Purification

Guest: Zhao Puya, Head of Downstream Technology at Cayman Biopharm

14:10-14:30 Report: Challenges and Strategies in Complex Antibody Purification Processes

Guest: Zhu Ying, Head of Downstream Process, Zhenge Biotechnology

14:30-14:50 Q&A

Masterclass

14:50-15:30 Report: Biotherapeutic Contamination Control Strategy and Inspection Deficiencies

Guest: Hongyu Tan, a senior domestic pharmaceutical GMP expert and former core inspector at CFDI.

15:30-16:00 Tea Break Networking

ADC Manufacturing Process and Quality Control

16:00-16:20 Report: Strategy and Practice for Comparability Studies of ADC DrugsNEW

Guest: Qu Yaocheng, Vice Director of Quality Control Department, Sinopharm Crosslink

16:20-16:40 Report: Key Points on ADC Special QC Strategy, Hardware Facilities, and Workshop Layout (Draft)

Guest: Professor Park, former head of the Drug GMP Inspection Team at the National Medical Products Administration

16:40-17:00 Report: Iterative CMC Strategy Upgrade Overcomes Scaling Challenges for Next-Generation Conjugate Drugs

Guest: Hongbin Song, Senior Director of ADC CMC at Innovent Biologics

17:00-17:20 Report: Quality Research and Control Strategy for XDC Drugs

Guest: Xu Ying,皓元医药 (Hao Yuan Pharmaceutical), Director / Head of ARD

Report: Analytical Characterization Challenges for Complex Molecules (ADCs, Bispecific Antibodies, and Fusion Proteins)

Guest: Mingze Sun, CMC Director at Tian Guangshi Biotech

17:40-17:50 Q&A

11 5 [Venue 2]

CGT R&D Innovation Forum

09:50-10:10 Report: Key Considerations in Developing CAR-T Therapies In Vivo

Guest: Hana He, Senior Director of R&D at Fosun Kary

10:10-10:30 Report: Development of In Vivo LNP Delivery Systems

Guest: Gu Yongjun, Wiszen Biotech, Partner & Head of CMC and Intellectual Property

High-level Strategy

11:00-11:50 Interview: How CGT Creates a True Closed Loop of "Innovation, Compliance, and Accessibility"NEW

Moderator: Chen Lijing, Vice President and COO, Jinweike Bio

Guests: Tan Binghe, CTO of Bionuo Biopharma; Wang Yue, Executive Director and Chair of the Cell and Gene Product Regulatory Research Committee at the China Association for Pharmaceutical Administration; He Ruina, Senior R&D Director at Fosun Karyopharm.

11:50-12:30 Interview: How Nucleic Acid Drugs Bridge the Gap from Technology Platform to Pipeline

Moderator: Zhang Zheng, Head of Southwest Investment at Huage Capital

Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center

Gu Yongjun, Vazson Bio, Partner & Head of CMC and Intellectual Property Li Jiangguang, Haichang Bio, CSO

Innovative R&D and Scalable Production of Peptide Drugs

13:30-13:50 Report: CR059: Long-Acting Efficacy of Circular RNA Encoding a GLP-1 Analog

Guest: Peiya, Chief Director of Early Drug R&D at PegBio

13:50-14:10 Report: Discovery and Engineering of Metabolic Polypeptide Drugs

Guest: Nie Yunyu, Chief Scientist of Metabolic Peptide Engineering at Innovent Biologics

14:10-14:30 Report: Natural Peptide Library & AI Discovery Platform

Guest: Liu Lulu, BD Director, PedBio

14:30-14:50 Report: Formulation Development Direction (Provisional)

Speaker: Yang Fengyun, Director of Formulation Development, Gansun Pharmaceutical

14:50-15:10 Report: Peptide Drug Process Scale-Up and Large-Scale Production (Provisional)

Guest: Li Changfeng, Senior R&D Supervisor, Chemical Macromolecules Division, AuroChem (Catalyst)

15:10-15:30 Report: Risk-Based Impurity Studies for GLP-1 Recombinant DrugsNEW

Guest: Liu Hedong, Senior Manager of Microbial Process Development Platform & Hengqin Early Development Platform, Federal Biotech

15:30-16:00 Tea Break Networking

Innovative Development of Nucleic Acid Drugs and Extracellular Delivery Innovations

16:00-16:20 Report: From COVID-19 to Oncology — The Paradigm Shift in mRNA Therapy Commercialization

Guest: Li Weimin, President of Preclinical R&D at Abogen

16:20-16:40 Report: Dual-Target siRNA Drug

Guest: Yu Shuowen, Director of Nucleic Acid Medicinal Chemistry at Xianyan Bio

16:40-17:00 Report: From Identification to Delivery: Applications of Nucleic Acid Aptamers in Extrahepatic Targeted Delivery

Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center

17:00-17:20 Report: Novel Lipid Nanoparticle-Based Nucleic Acid Delivery System

Guest: Li Jianguang, Haichang Biopharma, CSO

11/5 [Venue 3]

11:00-13:00 Exclusive Lunch

14:00-15:30 Executive Closed-Door Meeting

High-Level Closed-Door Meeting: Western Pharmaceutical Companies' Strategy and Choices in the AI Era

30 C-level executives and technical leaders from pharma/biotech

14:00-14:20 Report: How R&D Systems Are Reimagined with AI — From Target to Candidate Molecule

14:20-14:40 Report: How R&D Teams Are Using AI to Rebuild Knowledge Management and Cross-Functional Collaboration

14:40-15:30 Discussion: From "Heard It" to "Thought Through It" — Three Key Questions for AI Decision-Making

Outline

1: Should you join now? — Strategic timing assessment

2: How to Spend Your First Budget — Investment and Path

3 How to Select the Right Partner: Vetting and Risk Control

AI In Drug Discovery

16:00-16:20 Report: AI Antibody De Novo Design and Agent Platform Empowering Antibody Drug Discovery

Guest: Wang Tianyuan, CEO of Combiotech

16:20-16:40 Report: Data Security for AI in Biopharmaceutical Companies: From Knowledge Retrieval to Agent Execution

Guest: Liu Qihé, TransBio, Head of AI Development

16:40-17:00 Report: Intelligent Automation Discovery Platform - Differentiated Discovery Strategies for Next-Generation ADC/XDC Drugs

Guest: Zhang Hongwei, Chief Information Officer and Managing Director of Beijing at Kede Pharma

17:00-17:10 Q&A

11 6 [Venue 1]

Regulations and On-site Verification

09:00-09:20 Report: Scientific Regulation, Innovative Drug Development for Benefit

Guest: Ran Zhang, Beihe Kangcheng, Chief Regulatory Advisor

09:20-09:40 Report: Regulatory Strategy for Dual IND Filing of Innovative Drugs in China and the USNEW

Guest: Lei Juan, Registration Director, Hansi Aite

09:40-10:00 Report: Promoting Research through Regulation — Key Points for Clinical Evaluation in New Drug Marketing Applications

Guest: Chen Yangqi, Chengdu Xuyuan Biology, COO

10:00-10:20 Report: Differences in Pharmaceutical Registration Submissions and CMC Regulation Between Domestic and International Markets

10:20-10:30 Q&A

10:30-11:00 Tea Break Networking

Commercialization of Biologics Manufacturing

11:00-11:20 Report: Entrusted Production Management Under the MAH SystemNEW

Guest: He Yanchao, Simcere Pharmaceutical Group, Head of Quality/Qualified Person

11:20-11:40 Report: Key Success Factors for Technology Transfer (Provisional)

Guest: Li Hongcheng, Director of Upstream Process Development, Sinopharm Jinke

11:40-12:00 Report: Key Elements and Practices for Pre-Market Commercial Manufacturing in Biopharmaceuticals

Guest: Yang Shiming, Director of Production, Chubb Bio

12:00-12:20 Report: Mass Production Reshapes the Global Bio-Manufacturing Landscape

Guest: Liu Aibing, CMC Director at Bibo Biological

12:20-12:30 Q&A

12:30-13:30 Lunch Chat

AI for Pharma: Masterclass

13:30-14:30 Report: Biopharmaceuticals – Planning, Building, and Excelling in Smart Digital Factories

Guest: Li Shude, former Chief Manufacturing Officer of China Resources Biology

AI-Enabled CMC Development for Biopharmaceuticals

14:30-14:50 Report: Research on AI Digitalization, Compliance, and Enterprise Benefits

Guest: Ma Jun, former Vice President of Junshi Biosciences

14:50-15:10 Report: AI-Empowered CMC and Compliance Considerations for Biologics

Guest: Dongqiang Lin, Zhejiang University, Professor

AI-Driven Commercial Biopharmaceutical Manufacturing

15:10-15:30 Report: Digital Transformation of Biopharmaceutical Manufacturing:

Henlius: Practices and Insights

Guest: Wei Gong, General Manager of ADC Development and Clinical Manufacturing at MacroGenics

15:30-15:50 Report: The Path and Practice of Digital Intelligence Advancement for Pharmaceutical Enterprises

Guest: Zhu Xiaofeng, Deputy General Manager of the Intelligent Data Department, China Resources Double Crane

15:50-16:30 Interview: Digital Intelligence Breakthrough and Efficiency Revolution in Commercial Biopharmaceutical Manufacturing

Guest: Ma Jun, former Vice President of Junshi Biosciences

Dongqiang Lin, Zhejiang University, Professor

Sheng Zhe, Director of Intelligent Data Department, CR SanheNEW

Li Shude, former Chief Manufacturing Officer at China Resources Biology

Shiming Yang, Bu Chang Bio, Production Director

Tan Hongyu, a senior domestic GMP expert in the pharmaceutical industry and former core inspector at CFDI.

11 6 [Venue 2]

Innovative R&D of Complex Molecules

09:00-09:20 Report: Development of Bispecific ADCs and Dual-Payload ADCs

09:20-09:40 Report: Innovative ADC Development (Tentative)

Guest: Zhenwei Miao, Chairman and CEO of Ake Rui Si & Ying Bai Rui

09:40-10:00 Report: Pending

Guest: Song Xiangrong, Founder of Vistron Bio

10:00-10:20 Report: Progress in KRAS Inhibitor Development

Guest: Li Yingfu, Founder & Chairman of Haibowei Pharmaceuticals

10:20-10:30 Q&A

10:30-11:00 Tea Break Networking

Innovative R&D and CMC Development Strategies for Radiopharmaceuticals

11:00-11:40 Interview: Industrial Breakthrough and Commercial Path Selection for the Full Nuclear Medicine Chain

Host: Niun Xingle, Huajin Capital

Guest: Chen Dianjun, President and CSO of Chengdu Xingrui Jingxuan Biotechnology

Bai Ge, Guotong New Drugs, COO

Wang Zheng, CEO of Sinotrac Nuclear Medicine

Xiahai Hong, Chief Scientist at Guodian Tuhe Chuangxin (Chongqing) Technology Co., Ltd.

11:40-12:00 Report: The Critical Role of Novel Metal Chelators in Radiopharmaceutical Development

Guest: Wang Zheng, CEO of Sinotrac Nuclear Medicine

12:00-12:20 Report: Three Major Challenges in Producing Alpha Emitters via Medium- and High-Energy Proton AcceleratorsNEW

Guest: Xia Haihong, Chief Scientist, SPIC Nuclear Isotope Innovation (Chongqing) Technology Co., Ltd.

12:20-12:30 Q&A

12:30-13:30 Lunch Chat

Innovative CGT Therapy Development

13:30-13:50 Report: Development and Progress of rAAV Gene Therapy for Aging-Related Diseases

Guest: Dong Biao, Founder of Zhishan Weixin

13:50-14:10 Report: Research and Application of Cytoimmune Cell Therapy in Preventing Tumor Recurrence

Guest: Liu Dun, Vice President of Saide Biotech

14:10-14:30 Report: Progress in MSC Therapy for Liver Disease (Tentative)

Guest: Tan Yi, Vice President and Director of R&D at Qilu Cell Therapy

14:30-14:50 Report: Advances in Drug Research Derived from Pluripotent Stem Cells

Guest: Yan Xiang, Director of R&D, CloudTest Medicine

Innovative CGT Therapy Process Development and Scalable Manufacturing

14:50-15:10 Report: Key Points for CGT Production Verification

Guest: Teacher Tu, Regulatory Expert

15:10-15:30 Report: The World's First Gene Therapy Drug Development Platform Based on a Dual-Plasmid Process

Guest: Chen Lijing, COO/VP of Jinweike Bio

15:30-15:50 Report: Clinical Practice for Quality Control Standards of Small Extracellular Vesicles

Guest: Yang Shuangshuang, Research and Development Manager, Qilu Cell Therapy

15:50-16:10 Report: Automated Closed-System Stem Cell Production

Guest: Wu Shouliang, Deputy Director of Production Technology at Sino-Union

11/6 [Venue 3]

AI In Drug Discovery

09:10-09:30 Report: AI-Driven Nucleic Acid Drug Development and Clinical Translation

Guest: Liang Zhang, Researcher at the Hangzhou Institute of Medicine, Chinese Academy of Sciences

09:30-09:50 Report: Discovery of Novel Tumor Immunotherapy Targets and New Drug Development Based on Artificial Intelligence

Guest: Shijun Shi, Professor at Chengdu University of Traditional Chinese Medicine

09:50-10:30 Interview: The "Last Mile" of AI Drug Discovery – Bridging the Gap from Molecular Generation to Clinical Success

Host: Wang Tianyuan, CEO of Combi-Bio

Guest: Shi Sanjun, Professor, Chengdu University of Traditional Chinese Medicine

Liu Qihé, TransInfo Biotech, Head of AI Development

Zhang Liang, Researcher, Hangzhou Institute of Medicine, Chinese Academy of Sciences

Complex Molecular Process Development

11:00-11:20 Report: Formulation Stability and Process Scale-up Challenges

11:20-11:40 Report: Quality System Resilience Behind FDA's Three Inspections

11:40-12:30 Interview: The Evolution of CMC Across Stages – From Technical Challenges to Commercial SuccessNEW

Moderator: Tang Defang, Vice President of Jingze Bio

Guest: Ran Gugu, Salubris (Chengdu), Director of Project Management

Song Qingguo, Founder of Guanlan (Hong Kong) Medicine

Small-Molecule Innovative Development and Manufacturing

13:30-13:50 Report: Discovery of Novel Tumor Immunotherapy Targets and New Drug Development Based on Artificial Intelligence

Guest: Shijun Shi, Professor at Chengdu University of Traditional Chinese MedicineNEW

13:50-14:10 Report: Strategies for Enhancing Solubility of Poorly Soluble Small Molecule Drugs

14:10-14:30 Report: Formulation Strategy for Modified New Drugs (Category 2)

14:30-15:30 Discussion: Ecological Gaps and Synergistic Pathways in Small-Molecule Drug Innovation

Share to:

Related Articles

Bidding Never Stops: BPD Match Sparks a Sourcing and Procurement Surge

Read more →

AI for Pharma 2026 Concludes Successfully: Empowering Drug Discovery with AI, One Step Further

Read more →

Register for the BPD Biologics Process Development Conference

Connect with industry leaders and explore the frontiers of biopharmaceutical process innovation

Sign Up Now
沪ICP备2021023038号-10